RGCC and breast carcinoma: In conclusion, our findings show that the combination of carboplatin, paclitaxel, and RGCC inhibition can act synergistically to suppress breast cancer lung metastasis, which could bring therapeutic benefits for TNBC patients with lung metastasis.